Mazalvix (Mesalazine)

Mesalazine acts locally in the gastrointestinal tract. It inhibits cyclooxygenase and lipoxygenase enzymes, scavenges free radicals, and modulates NF‑κB signaling pathways, thereby decreasing the production of inflammatory mediators such as prostaglandins and leukotrienes that drive bowel inflammation.

The specific dose of Mazalvix is determined by the prescribing clinician based on the patient’s disease severity, location, and response to therapy. Dosage adjustments are made according to clinical guidelines and individual patient factors.

Safety data for mesalazine in pregnancy and lactation are limited. Clinicians should weigh the potential benefits against possible risks and consider alternative therapies if appropriate. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mazalvix delivers the same active ingredient, mesalazine, as other 5‑ASA products. Differences may lie in formulation, release characteristics, or excipients, which can affect tolerability and dosing frequency. Clinical efficacy is generally comparable when equivalent doses are used.

Mazalvix should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mazalvix is taken orally, usually with water. The exact administration schedule—such as once or multiple times daily—depends on the prescribed dose and the formulation provided by the prescriber.

Serious risks include severe allergic reactions (anaphylaxis), significant gastrointestinal bleeding, liver injury, pancreatitis, acute kidney injury, and cardiac inflammation such as myocarditis. Patients should be instructed to seek immediate medical attention if they experience symptoms like rash, blood in stool, jaundice, severe abdominal pain, or chest discomfort.

Mazalvix is contraindicated in individuals with known hypersensitivity to mesalazine, other 5‑ASA compounds, or any of the product’s excipients. It should also be avoided in patients with severe renal or hepatic impairment unless closely monitored by a specialist.